Format

Send to

Choose Destination
Cancer Discov. 2011 Jun;1(1):25-8. doi: 10.1158/2159-8274.CD-11-0051. Epub 2011 Jun 1.

Toward molecular imaging-driven drug development in oncology.

Author information

1
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. e.g.e.de.vries@int.umcg.nl

Abstract

With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed.

PMID:
22586317
DOI:
10.1158/2159-8274.CD-11-0051
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center